Back to News
Market Impact: 0.35

AbbVie Completes Acquisition of Apogee Therapeutics

Source: PR Newswire

M&A & RestructuringHealthcare & BiotechCompany FundamentalsCorporate Guidance & Outlook

AbbVie’s acquisition (via Apogee) deepens its immunology pipeline by adding diverse late-stage assets targeting dermatologic, respiratory, and other inflammatory diseases. The lead candidate, zumilokibart, is a half-life extended monoclonal antibody targeting IL-13 and is described as late-stage in development, supporting continued expansion of AbbVie’s immunology growth platform.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

mildly positive

Sentiment Score

0.25

Ticker Sentiment

ABBV0.35
APOG0.30

More News

From AllMind Research

Browse all research